ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of...Epithelial ovarian, fallopian tube, or primary peritoneal cancer...in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, for stage III or IV disease following initial surgical resection...in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens...in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by ZIRABEV as a single agent, for platinumsensitive recurrent disease.